BRIDGEWATER, N.J., Nov. 2, 2016
BRIDGEWATER, N.J., Nov. 2, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, India, announces today the launch of Amlodipine + Olmesartan Medoxomil Tablets, (5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg), a bioequivalent generic version of Azor®1 Tablets into the US market.
Amlodipine + Olmesartan Medoxomil Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the United States Food & Drug Administration.
About Ajanta Pharma
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.
For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
1 Azor® is a registered trademark of Daiichi Sankyo Inc .
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-amlodipine--olmesartan-medoxomil-tablets-300355868.html
SOURCE Ajanta Pharma USA Inc.PR Newswire
Last updated on: 02/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.